Combination pharmacotherapy for stopping smoking: What advantages does it offer?

Drugs

Volumn 70, Issue 6, 2010, Pages 643-650

  Ebbert, Jon O ^a   Hays, J Taylor ^a   Hurt, Richard D ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CLONIDINE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NICOTINIC RECEPTOR; NORTRIPTYLINE; PLACEBO; VARENICLINE;

CLINICAL PRACTICE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; MONOTHERAPY; NAUSEA; NICOTINE REPLACEMENT THERAPY; NOTE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; SEIZURE; SLEEP DISORDER; SMOKING CESSATION; TOBACCO DEPENDENCE; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

ANIMALS; BUPROPION; DRUG THERAPY, COMBINATION; HUMANS; NICOTINE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SMOKING; SMOKING CESSATION;

NICOTIANA TABACUM;

EID: 77951044898     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11536100-000000000-00000     Document Type: Note

References (41)

1. World Health Organization. The facts about smoking and health. 2006 May 30 [online]. Available from URL: http://www.wpro.who.int/media-centre/fact- sheets/fs-20060530.htm [Accessed 2008 Sep 24]
2. U.S. Department of Health and Human Services. The health consequences of smoking: nicotine addiction. A report of the Surgeon General. Washington, DC: U.S. Government Printing Office, 1988. DHHS publication no. 88-8406
3. Koob GF. Drugs of abuse: anatomy, pharmacology and function of reward pathways. Trends Pharmacol Sci 1992 May; 13 (5): 177-184
4. U.S. Department of Health and Human Services. The health benefits of smoking cessation: a report of the Surgeon General, 1990. Washington, DC: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Office on Smoking and Health, 1990. Publication no. (CDC) 90-8416
5. Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Rockville (MD): U.S. Department of Health and Human Services, Public Health Service, 2008 May
6. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 47-55
7. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of var enicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006 Jul 5; 296 (1): 56-63
8. Stapleton JA, Watson L, Spirling LI, et al. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction 2008 Jan; 103 (1): 146-154 (Pubitemid 350233424)
9. Aubin HJ, Bobak A, Britton JR, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008 Aug; 63 (8): 717-724
10. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2008; (3): CD006103
11. Hurt RD, Sachs DP, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med 1997 Oct 23; 337 (17): 1195-1202
12. Jorenby DE, Leischow SJ, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 1999; 340 (9): 685-691 (Pubitemid 29110752)
13. Ebbert JO, Sood A, Hays JT, et al. Treating tobacco de-pendence: review of the best and latest treatment options. J Thorac Oncol 2007 Mar; 2 (3): 249-256 (Pubitemid 47181332)
14. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008; (1): CD000146
15. Sweeney CT, Fant RV, Fagerstrom KO, et al. Combination nicotine replacement therapy for smoking cessation: rationale, efficacy and tolerability. CNS Drugs 2001; 15 (6): 453-467
16. Hajek P, West R, Foulds J, et al. Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler. Arch Intern Med 1999; 159: 2033-2038 (Pubitemid 29453591)
17. Puska P, Korhonen HJ, Vartiainen E, et al. Combined use of nicotine patch and gum compared with gum alone in smoking cessation: a clinical trial in North Karelia. Tob Control 1995; 4: 231-235
18. Kornitzer M, Boutsen M, Dramaix M, et al. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. Prev Med 1995; 24 (1): 41-47
19. Fagerstrom KO, Schneider NG, Lunell E. Effectiveness of nicotine patch and nicotine gum as individual versus combined treatments for tobacco withdrawal symptoms. Psychopharmacology (Berl) 1993; 111 (3): 271-277 (Pubitemid 23165255)
20. Croghan GA, Sloan JA, Croghan IT, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. Nicotine Tob Res 2003 Apr; 5 (2): 181-187
21. Blondal T, Gudmundsson LJ, Olafsdottir I, et al. Nicotine nasal spray with nicotine patch for smoking cessation: randomized trial with six year follow up. BMJ 1999; 318: 285-288 (Pubitemid 29195135)
22. Bohadana A, Nilsson F, Rasmussen T, et al. Nicotine in haler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 2000; 160: 3128-3134
23. Smith SS, McCarthy DE, Japuntich SJ, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. Arch Intern Med 2009 Dec 14; 169 (22): 2148-2155
24. Piper ME, Smith SS, Schlam TR, et al. A randomized place-bo-controlled clinical trial of 5 smoking cessation pharma-cotherapies. Arch Gen Psychiatry 2009 Nov;66 (11): 1253-1262
25. Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc 2007 Feb; 82 (2): 186-195 (Pubitemid 46198478)
26. George TP, Vessicchio JC, Sacco KA, et al. A placebo controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry 2008 Jun 1; 63 (11): 1092-1096
27. Grant KM, Kelley SS, Smith LM, et al. Bupropion and nicotine patch as smoking cessation aids in alcoholics. Alcohol 2007 Aug; 41 (5): 381-391
28. Hughes JR, Kalman D. Do smokers with alcohol problems have more difficulty quitting? Drug Alcohol Depend 2006 Apr 28; 82 (2): 91-102
29. Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psycho-pharmacol 2007 Aug; 27 (4): 380-386 (Pubitemid 47075510)
30. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med 2009 Apr 7; 150 (7): 447-454
31. Aveyard P, Johnson C, Fillingham S, et al. Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial. BMJ 2008 May 31; 336 (7655): 1223-1227 (Pubitemid 351809316)
32. Prochaska AV, Kick S, Steinbrunn C, et al. A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation. Arch Intern Med 2004 Nov 8; 164 (20): 2229-2233 (Pubitemid 39452983)
33. Hughes J, Stead L, Lancaster T. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2007; 1: CD000031
34. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bu-propion sustained-release combination therapy for smoking cessation. Nicotine Tob Res 2009 Mar; 11 (3): 234-239
35. Varenicline and bupropion for smoking cessation (CHAN-BAN) [ClinicalTrials.gov identifier NCT00935818]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2010 Mar 1]
36. Smith JW, Mogg A, Tafi E, et al. Ligands selective for al-pha4beta2 but not alpha3beta4 or alpha7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 2007 Feb; 190 (2): 157-170 (Pubitemid 46011176)
37. Faessel HM, Gibbs MA, Clark DJ, et al. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 2006 Dec; 46 (12): 1439-1448 (Pubitemid 44704204)
38. Ebbert JO, Burke MV, Hays JT, et al. Combination treat-ment with varenicline and nicotine replacement therapy. Nicotine Tob Res 2009 May; 11 (5): 572-576
39. Cornuz J, Gilbert A, Pinget C, et al. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison. Tob Control 2006 Jun; 15 (3): 152-159 (Pubitemid 43864869)
40. Schnoll RA, Patterson F, Wileyto EP, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. Ann Intern Med 2010 Feb 2; 152 (3): 144-151
41. Song F, Raftery J, Aveyard P, et al. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis. Med Decis Making 2002 Sep-Oct; 22 (5 Suppl.): S26-37